Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran versus placebo in adults with ASCVD or ASCVD-risk equivalents and elevated LDL-C
NL-OMON44477Phase 3Withdrawn
- Sponsor
- The Medicines Company
- Start
- Nov 2017
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing Inclisiran with Placebo (2 arms). Primary endpoints: Percentage change in LDL-C from baseline to Day 510 and Time-adjusted percentage change in LDL-C from baseline between Day 90 and Day 540. Planned start Nov 2017; status: withdrawn.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NL-OMON44477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44477.